Skip to content

Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model

Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings

US syringe funding ban impedes HIV and hepatitis C prevention

Bill McColl and Mary Beth Levin at the National HIV Prevention Conference. Photo by Liz Highleyman, hivandhepatitis.com

UK maintains the largest HIV epidemic in western Europe

Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure

Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued

Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection

Jurgen Rockstroh, presenting at AASLD 2015. Photo by Liz Highleyman, hivandhepatitis.com

Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients

National HIV Prevention Conference highlights progress and disparities

Anthony Fauci presenting at the 2015 National HIV Prevention Conference. Photo by Liz Highleyman, hivandhepatitis.com